BUYER POOL ANALYSIS
Selling a pharmacy to Private Equity / PE-Backed Roll-Up buyers
Private equity firms and PE-backed platform consolidators acquiring for roll-up, add-on, or platform plays. Pricing tends to lead the market for fee-viable scale, with multi-bidder competitive processes above the EBITDA floor.
Quick answers
- How many disclosed transactions?
- 16 deals total (16 from 2018+), filtered to Private Equity / PE-Backed Roll-Up acquirers of pharmacy businesses.
- Most active buyers
- Frazier Healthcare Partners (2) · Court Square Capital and WindRose Health (1) · Sycamore Partners Management, L.P. (1) · PCP Management Inc. (1) · Vistria Group / General Atlantic / Nautic Partners (1) · Neighbourly Pharmacy Inc. (:NBLY) (1)
- What would this buyer pool pay for my business?
- Run the ExitValue.ai calculator to see your pharmacy priced against the 16 disclosed private equity / pe-backed roll-up transactions in this segment. The engine surfaces the specific multiples that apply to your size, margin, and growth profile.
Recent disclosed deals
Private Equity / PE-Backed Roll-Up acquisitions of pharmacy businesses with named target and named acquirer.
| Year | Target | Acquirer |
|---|---|---|
| 2025 | Soleo Health | Court Square Capital and WindRose Health |
| 2025 | Walgreens Boots Alliance, Inc. | Sycamore Partners Management, L.P. |
| 2024 | BioMatrix | Frazier Healthcare Partners |
| 2023 | Neighbourly Pharmacy Inc. | PCP Management Inc. |
| 2022 | PANTHERx | Vistria Group / General Atlantic / Nautic Partners |
| 2022 | Rubicon Pharmacies Canada Inc. | Neighbourly Pharmacy Inc. (:NBLY) |
What this buyer pool prices for
Private equity acquirers price for scale and roll-up arbitrage. They pay up for businesses that fit a platform thesis - recurring revenue mix above 30%, technician/professional depth, clean financials, and a management layer that survives integration. A pharmacy that fits the platform thesis prices materially above what an individual buyer would pay because PE is buying a platform piece, not an owner-operated shop.
Methodology note
Deal flow shown reflects disclosed M&A transactions in the ExitValue.ai database, filtered to pharmacy businesses acquired by private equity / pe-backed roll-up buyers. Deal counts shown reflect deals with disclosed financials only - total transaction count for this buyer pool is typically 2-3x larger. The valuation engine reveals the specific multiples that apply to your business when you run the calculator above. Full methodology
What's your pharmacy worth to private equity / pe-backed roll-up?
12-input M&A-grade workup with sellability score, named comparable deals, and AI-written commentary. 2 minutes.
- ✓Sellability score with 5-driver breakdown and lift estimates
- ✓Named comparable M&A transactions in your sub-vertical
- ✓AI-written analysis grounded in your specific inputs
Engine-grounded estimate. Comparable private equity / pe-backed roll-up deals on the full results page.
More on pharmacy valuations
- Value a medical practice
- Value a dental practice
- Value a veterinary practice
- Value a pharmacy· run the calculator
- Pharmacy median multiples· real-deal benchmarks
- Who buys pharmacy businesses?· active buyers
- Recent deal: University Compounding Pharmacy· comparable transaction
- Who acquired University Compounding Pharmacy?· buyer profile